Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab® platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.

“Pfizer has been one of our most ardent supporters over the years, both as a key customer and as an early investor”

Entelos' Metabolism PhysioLab combines physiology and individual behavior to support research on two metabolic disorders whose incidence continues to increase worldwide—obesity and diabetes. Through its scientific and technical staff and patented technologies, Entelos provides its customers, such as Pfizer, with expert knowledge in these areas. The Metabolism PhysioLab platform reproduces many of the behaviors and underlying biological attributes of metabolism in diverse patient types. Entelos' "virtual patients" are used for testing a compound or target's efficacy in the platform, individually or in combination with other targets, compounds or the current standards of care. Due to the vast heterogeneity of these diseases, virtual patients have been created that span the disease continuum and progression, from lean, insulin-sensitive to severely obese, type 2 diabetes.

The expanded license terms will further advance the translation of Pfizer's preclinical data to clinical response, integrate and guide experimental work which may lead to an improved quantitative understanding of target and disease mechanisms, and provide a platform for assessing different combination strategies to support partnering and competitive differentiation strategies.

"Pfizer has been one of our most ardent supporters over the years, both as a key customer and as an early investor" said Julie Thomas Goggin, Entelos' Chief Executive Officer. "We are thrilled that our highly predictive, established Metabolism Physiolab platform will be available to Pfizer on a perpetual basis to help accelerate its compound development. We look forward to continuing to expand our long-standing and successful relationship with such an important and valued stakeholder."